TABLE OF CONTENTS
1 INTRODUCTION 91
1.1 OBJECTIVES OF THE STUDY 91
1.2 MARKET DEFINITION 91
1.3 OVERVIEW OF THE NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET 91
1.4 CURRENCY AND PRICING 94
1.5 LIMITATIONS 94
1.6 MARKETS COVERED 94
2 MARKET SEGMENTATION 98
2.1 MARKETS COVERED 98
2.2 GEOGRAPHICAL SCOPE 99
2.3 YEARS CONSIDERED FOR THE STUDY 100
2.4 DBMR TRIPOD DATA VALIDATION MODEL 101
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 104
2.6 MULTIVARIATE MODELLING 105
2.7 MARKET END USER COVERAGE GRID 106
2.8 PRODUCT LIFELINE CURVE 107
2.9 DBMR MARKET POSITION GRID 108
2.10 VENDOR SHARE ANALYSIS 109
2.11 SECONDARY SOURCES 110
2.12 ASSUMPTIONS 110
3 EXECUTIVE SUMMARY 111
4 PREMIUM INSIGHTS 114
4.1 PESTEL ANALYSIS 115
4.2 PORTERS FIVE FORCES MODEL 116
5 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 117
6 EPIDEMIOLOGY 119
7 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 120
8 MARKET OVERVIEW 123
8.1 DRIVERS 125
8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 125
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 125
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 126
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 126
8.2 RESTRAINTS 127
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 127
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 127
8.3 OPPORTUNITIES 128
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 128
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 129
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 129
8.4 CHALLENGES 130
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 130
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 130
9 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131
9.1 OVERVIEW 132
9.2 IMAGING TEST 135
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 136
9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 136
9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 136
9.2.2.2 MR ANGIOGRAPHY (MRA) 137
9.2.3 ULTRASOUND 137
9.2.3.1 ABDOMINAL ULTRASOUND 137
9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 137
9.2.4 CHOLANGIOPANCREATOGRAPHY 137
9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 138
9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 138
9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 138
9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 138
9.2.6 OTHERS 138
9.3 BIOPSY 139
9.3.1 CT-GUIDED NEEDLE BIOPSY 140
9.3.2 FINE NEEDLE ASPIRATION (FNA) 140
9.3.3 CORE NEEDLE BIOPSY 140
9.3.4 OTHERS 140
9.4 BLOOD TEST 140
9.4.1 LIVER FUNCTION TEST 141
9.4.2 TUMOR MARKER 141
9.4.2.1 CA 19-9 BIOMARKER TEST 142
9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 142
9.4.2.3 CA 50 MARKER TEST 142
9.4.2.4 OTHERS 142
9.4.3 OTHERS 142
9.5 GENOMIC TEST 143
9.6 OTHERS 144
10 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 145
10.1 OVERVIEW 146
10.2 STAGE IV 149
10.3 STAGE III 149
10.4 STAGE II 150
10.4.1 STAGE IIA 151
10.4.2 STAGE IIB 151
10.5 STAGE I 151
10.5.1 STAGE IA 152
10.5.2 STAGE IB 152
10.6 STAGE 0 153
11 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 154
11.1 OVERVIEW 155
11.2 EXOCRINE TUMORS 158
11.2.1 INSTRUMENT-BASED PRODUCTS 159
11.2.2 PLATFORM-BASED PRODUCTS 159
11.2.3 KITS AND REAGENTS 159
11.2.4 OTHER CONSUMABLES 159
11.3 NEUROENDOCRINE TUMORS 159
11.3.1 INSTRUMENT-BASED PRODUCTS 160
11.3.2 PLATFORM-BASED PRODUCTS 160
11.3.3 KITS AND REAGENTS 161
11.3.4 OTHER CONSUMABLES 161
12 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 162
12.1 OVERVIEW 163
12.2 INSTRUMENT-BASED PRODUCTS 166
12.2.1 IMAGING 167
12.2.2 BIOPSY 167
12.3 PLATFORM-BASED PRODUCTS 167
12.3.1 NEXT-GENERATION SEQUENCING 168
12.3.2 MICROARRAYS 168
12.3.3 PCR 168
12.3.4 OTHERS 169
12.4 KITS AND REAGENTS 169
12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 170
12.4.1.1 ELISA TEST KITS 170
12.4.1.2 CASETTE TEST KITS 170
12.4.1.3 OTHERS 170
12.4.2 CEA PANCREATIC CANCER TEST KITS 171
12.4.2.1 ELISA TEST KITS 171
12.4.2.2 CASETTE TEST KITS 171
12.4.2.3 OTHERS 171
12.5 OTHER CONSUMABLES 171
13 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 173
13.1 OVERVIEW 174
13.2 FLUORESCENT IN SITU HYBRIDIZATION 177
13.3 NEXT GENERATION SEQUENCING 178
13.4 FLUORIMMUNOASSAY 179
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 180
13.6 IMMUNOHISTOCHEMICAL 181
13.7 OTHERS 182
14 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 183
14.1 OVERVIEW 184
14.2 SCREENING 187
14.2.1 INSTRUMENT-BASED PRODUCTS 188
14.2.2 PLATFORM-BASED PRODUCTS 188
14.2.3 KITS AND REAGENTS 188
14.2.4 OTHER CONSUMABLES 188
14.3 DIAGNOSTIC AND PREDICTIVE 188
14.3.1 INSTRUMENT-BASED PRODUCTS 189
14.3.2 PLATFORM-BASED PRODUCTS 189
14.3.3 KITS AND REAGENTS 189
14.3.4 OTHER CONSUMABLES 189
14.4 PROGNOSTIC 190
14.4.1 INSTRUMENT-BASED PRODUCTS 191
14.4.2 PLATFORM-BASED PRODUCTS 191
14.4.3 KITS AND REAGENTS 191
14.4.4 OTHER CONSUMABLES 191
14.5 RESEARCH 191
14.5.1 INSTRUMENT-BASED PRODUCTS 192
14.5.2 PLATFORM-BASED PRODUCTS 192
14.5.3 KITS AND REAGENTS 192
14.5.4 OTHER CONSUMABLES 192
15 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 193
15.1 OVERVIEW 194
15.2 HOSPITALS 197
15.3 DIAGNOSTIC CENTERS 197
15.4 CANCER RESEARCH CENTERS 198
15.5 ACADEMIC INSTITUTES 199
15.6 AMBULATORY SURGICAL CENTERS 200
15.7 OTHERS 201
16 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 202
16.1 OVERVIEW 203
16.2 DIRECT TENDER 206
16.3 RETAIL SALES 207
16.4 OTHERS 208
17 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 209
17.1 NORTH AMERICA 210
17.1.1 U.S. 224
17.1.2 CANADA 233
17.1.3 MEXICO 242
18 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 251
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 251
19 SWOT ANALYSIS 252
20 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET 253
20.1 CANON MEDICAL SYSTEMS CORPORATION 253
20.1.1 COMPANY SNAPSHOT 253
20.1.2 REVENUE ANALYSIS 253
20.1.3 COMPANY SHARE ANALYSIS 254
20.1.4 PRODUCT PORTFOLIO 254
20.1.5 RECENT DEVELOPMENT 254
20.2 KONINKLIJKE PHILIPS N.V. 255
20.2.1 COMPANY SNAPSHOT 255
20.2.2 REVENUE ANALYSIS 255
20.2.3 COMPANY SHARE ANALYSIS 256
20.2.4 PRODUCT PORTFOLIO 256
20.2.5 RECENT DEVELOPMENTS 256
20.3 SIEMENS HEALTHCARE GMBH 258
20.3.1 COMPANY SNAPSHOT 258
20.3.2 REVENUE ANALYSIS 258
20.3.3 COMPANY SHARE ANALYSIS 259
20.3.4 PRODUCT PORTFOLIO 259
20.3.5 RECENT DEVELOPMENT 260
20.4 GRAIL 261
20.4.1 COMPANY PROFILE 261
20.4.2 COMPANY SHARE ANALYSIS 261
20.4.3 PRODUCT PORTFOLIO 262
20.4.4 RECENT DEVELOPMENT 262
20.5 MYRIAD GENETICS, INC. 263
20.5.1 COMPANY SNAPSHOT 263
20.5.2 REVENUE ANALYSIS 263
20.5.3 COMPANY SHARE ANALYSIS 264
20.5.4 PRODUCT PORTFOLIO 264
20.5.5 RECENT DEVELOPMENT 264
20.6 BD 265
20.6.1 COMPANY SNAPSHOT 265
20.6.2 REVENUE ANALYSIS 265
20.6.3 PRODUCT PORTFOLIO 266
20.6.4 RECENT DEVELOPMENT 266
20.7 BODITECH MED INC. 267
20.7.1 COMPANY PROFILE 267
20.7.2 PRODUCT PORTFOLIO 267
20.7.3 RECENT DEVELOPMENT 267
20.8 ABBOTT (2022) 268
20.8.1 COMPANY SNAPSHOT 268
20.8.2 REVENUE ANALYSIS 268
20.8.3 PRODUCT PORTFOLIO 269
20.8.4 RECENT DEVELOPMENT 269
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION 270
20.9.1 COMPANY SNAPSHOT 270
20.9.2 REVENUE ANALYSIS 270
20.9.3 PRODUCT PORTFOLIO 271
20.9.4 RECENT DEVELOPMENT 271
20.10 ACCUBIOTECH CO., LTD. 272
20.10.1 COMPANY PROFILE 272
20.10.2 PRODUCT PORTFOLIO 272
20.10.3 RECENT DEVELOPMENTS 272
20.11 AGILENT TECHNOLOGIES, INC. 273
20.11.1 COMPANY PROFILE 273
20.11.2 REVENUE ANALYSIS 273
20.11.3 PRODUCT PORTFOLIO 274
20.11.4 RECENT DEVELOPMENT 274
20.12 CREATIVE BIOLABS. 275
20.12.1 COMPANY PROFILE 275
20.12.2 PRODUCT PORTFOLIO 275
20.12.3 RECENT DEVELOPMENT 275
20.13 CTK BIOTECH, INC. 276
20.13.1 COMPANY PROFILE 276
20.13.2 PRODUCT PORTFOLIO 276
20.13.3 RECENT DEVELOPMENT 276
20.14 DIASOURCE 277
20.14.1 COMPANY SNAPSHOT 277
20.14.2 PRODUCT PORTFOLIO 277
20.14.3 RECENT DEVELOPMENT 277
20.15 LABORATORY CORPORATION OF AMERICA HOLDINGS 278
20.15.1 COMPANY SNAPSHOT 278
20.15.2 REVENUE ANALYSIS 278
20.15.3 PRODUCT PORTFOLIO 279
20.15.4 RECENT DEVELOPMENTS 279
20.16 LEE BIOSCIENCE 280
20.16.1 COMPANY SNAPSHOT 280
20.16.2 PRODUCT PORTFOLIO 280
20.16.3 RECENT DEVELOPMENT 280
20.17 MERIDIAN BIOSCIENCE INC. 281
20.17.1 COMPANY PROFILE 281
20.17.2 PRODUCT PORTFOLIO 281
20.17.3 RECENT DEVELOPMENT 281

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.